Featured 13F manager
Palo Alto Investors LP Palo Alto Investors
Palo Alto, CA 23 processed 13Fs on this site · 2021 Q3–2026 Q2
- $724M
- 52 Positions
- 2026 Q2
- +10.7% QoQ
- Top 5 37.7%
Palo Alto Investors files Palo Alto Investors LP as a Form 13F. The latest book is 2026 Q2 at $724M, up 10.7% QoQ, led by Ptc Therapeutics, Acadia Pharmaceuticals, and Insmed.
Portfolio
top 5 37.7% · top 10 61.3%
- PTC - Ptc Therapeutics 10.4%
- ACAD - Acadia Pharmaceuticals 10.0%
- INSM - Insmed 6.1%
- MIRM - Mirum Pharmaceuticals 5.6%
- ANAB - Anaptysbio 5.6%
- BMRN - Biomarin Pharmaceutical 5.4%
- DYN - Dyne Therapeutics 5.1%
- UTHR - United Therapeutics 4.7%
- IRON - Disc Medicine 4.2%
- BIIB - Biogen 4.2%
- IOVA - Iovance Biotherapeutics 3.0%
- RARE — 2.8%
- Other 32.9%
AUM over time
Latest book
| PTC - Ptc Therapeutics | 10.36% | Reduce −0.3% | 918,846 | $81.57 | $75M | −2,761 | +$12M |
| ACAD - Acadia Pharmaceuticals | 10.01% | Reduce −0.3% | 2,864,096 | $25.30 | $72M | −8,599 | +$9M |
| INSM - Insmed | 6.10% | Reduce −0.3% | 413,980 | $106.62 | $44M | −1,289 | −$24M |
| MIRM - Mirum Pharmaceuticals | 5.64% | Add +7.3% | 348,808 | $117.07 | $41M | +23,633 | +$11M |
| ANAB - Anaptysbio | 5.63% | Reduce −5.4% | 603,489 | $67.50 | $41M | −34,672 | +$5M |
| BMRN - Biomarin Pharmaceutical | 5.40% | Reduce −0.4% | 682,777 | $57.22 | $39M | −2,405 | +$363K |
| DYN - Dyne Therapeutics | 5.06% | Reduce −0.3% | 1,647,521 | $22.21 | $37M | −5,451 | +$7M |
| UTHR - United Therapeutics | 4.69% | Reduce −0.4% | 62,587 | $541.83 | $34M | −222 | −$3M |
| IRON - Disc Medicine | 4.21% | Add +3.7% | 416,646 | $73.14 | $30M | +14,927 | +$5M |
| BIIB - Biogen | 4.19% | Reduce −0.3% | 140,279 | $216.06 | $30M | −440 | +$5M |
| IOVA - Iovance Biotherapeutics | 3.04% | Reduce −16.6% | 5,296,209 | $4.16 | $22M | −1,053,354 | −$255K |
| RARE — | 2.75% | Hold | 596,495 | $33.39 | $20M | — | — |
| NVCR - Novocure | 2.68% | Hold | 1,280,439 | $15.15 | $19M | — | — |
| SNDX - Syndax Pharmaceuticals | 2.61% | Hold | 864,986 | $21.86 | $19M | — | — |
| ANNX - Annexon | 2.33% | Hold | 2,948,090 | $5.71 | $17M | — | — |
| BCAX - Bicara Therapeutics | 2.26% | Hold | 550,408 | $29.69 | $16M | — | — |
| CDNA - Caredx | 2.09% | Hold | 531,870 | $28.50 | $15M | — | — |
| CLDX - Celldex Therapeutics | 2.06% | Add +34.9% | 399,856 | $37.21 | $15M | +103,448 | +$5M |
| CMPX - Compass Therapeutics | 1.76% | Add +285.1% | 5,831,813 | $2.19 | $13M | +4,317,309 | +$5M |
| ALKS - Alkermes | 1.76% | Hold | 242,560 | $52.39 | $13M | — | — |
| TRAX - First Tracks | 1.68% | New | 603,489 | $20.12 | $12M | +603,489 | +$12M |
| PRTA - Prothena | 1.55% | Reduce −5.4% | 1,143,155 | $9.79 | $11M | −65,413 | −$556K |
| TVTX - Travere Therapeutics | 1.32% | Reduce −27.3% | 167,525 | $56.81 | $10M | −62,928 | +$3M |
| TSHA - Taysha Gene Therapies | 1.31% | Hold | 1,391,382 | $6.81 | $9M | — | — |
| ACRS - Aclaris Therapeutics | 1.18% | Hold | 1,613,430 | $5.29 | $9M | — | — |
| AGIO - Agios Pharmaceuticals | 1.10% | Hold | 213,601 | $37.11 | $8M | — | — |
| CAPR — | 0.76% | Hold | 229,763 | $24.08 | $6M | — | — |
| ALGN - Align Technology | 0.73% | Reduce −24.4% | 31,389 | $168.66 | $5M | −10,131 | −$2M |
| ORKA - Oruka Therapeutics | 0.44% | Reduce −44.1% | 33,546 | $95.17 | $3M | −26,439 | +$250K |
| XENE - Xenon Pharmaceuticals | 0.43% | Hold | 51,345 | $60.36 | $3M | — | — |
| NBIX - Neurocrine Biosciences | 0.42% | Hold | 18,117 | $168.54 | $3M | — | — |
| EW - Edwards Lifesciences | 0.42% | Hold | 33,640 | $90.46 | $3M | — | — |
| STOK - Stoke Therapeutics | 0.38% | Hold | 84,631 | $32.72 | $3M | — | — |
| CYTK - Cytokinetics | 0.38% | Hold | 32,195 | $85.19 | $3M | — | — |
| PYXS - Pyxis Oncology | 0.36% | Reduce −14.5% | 864,277 | $3.01 | $3M | −146,233 | +$1M |
| EHTH - Ehealth | 0.31% | Hold | 1,482,797 | $1.49 | $2M | — | — |
| CRSP - Crispr Therapeutics AG | 0.30% | Hold | 39,605 | $54.54 | $2M | — | — |
| SGMT - Sagimet Biosciences -A | 0.27% | New | 250,000 | $7.73 | $2M | +250,000 | +$2M |
| NUVB - Nuvation Bio · CL A | 0.26% | Reduce −35.8% | 326,609 | $5.68 | $2M | −182,237 | −$328K |
| BNTX - Biontech Se- | 0.25% | Hold | 19,614 | $93.05 | $2M | — | — |
| CMPS - Compass Pathways | 0.23% | Hold | 115,616 | $14.15 | $2M | — | — |
| HUM - Humana | 0.22% | Hold | 3,985 | $397.22 | $2M | — | — |
| NAMS - Newamsterdam Pharma | 0.21% | New | 44,359 | $33.89 | $2M | +44,359 | +$2M |
| VSTM - Verastem | 0.16% | Add +25.8% | 309,685 | $3.82 | $1M | +63,592 | −$121K |
| MDGL - Madrigal Pharmaceuticals | 0.13% | Hold | 1,787 | $536.95 | $960K | — | — |
| URGN - Urogen Pharma | 0.12% | Hold | 24,500 | $36.80 | $902K | — | — |
| BCYC — | 0.12% | Hold | 201,890 | $4.24 | $856K | — | — |
| XERS - Xeris Biopharma | 0.11% | Hold | 104,410 | $7.92 | $827K | — | — |
| ABEO - Abeona Therapeutics | 0.09% | Hold | 108,865 | $6.18 | $673K | — | — |
| INSP - Inspire Medical Systems | 0.05% | Hold | 8,772 | $44.61 | $391K | — | — |
| PRQR - Proqr Therapeutics | 0.05% | Hold | 188,807 | $1.86 | $351K | — | — |
| ALDX - Aldeyra Therapeutics | 0.05% | Hold | 155,709 | $2.13 | $332K | — | — |
Showing top 50 of 52 by value
Exits / last held
not current holdings · last reported size, unchanged · gone vs 2026 Q1
| Stock | % of portfolio | Recent activity | Shares | Reported price* | Value | Share change | $ change |
|---|---|---|---|---|---|---|---|
| FOLD - Amicus | 2.46% | Exit | 0 | $14.46 | $16M | −1,113,045 | −$16M |
| DNLI - Denali Therapeutics | 0.69% | Exit | 0 | $19.20 | $5M | −234,582 | −$5M |
Filings history
20 periods · normalized AUM · open a period for holdings
| Period | Holdings | AUM | QoQ | Form | Filed | Filing ID |
|---|---|---|---|---|---|---|
| 2026 Q2 | 52 | $724M | +10.7% | RESTATEMENT | 8/19/2026 | 000207367926000102 |
| 2026 Q2 | 52 | $724M | — | RESTATEMENT | 8/18/2026 | 000207367926000101 |
| 2026 Q2 | 52 | $724M | — | 13F-HR | 8/17/2026 | 000207367926000096 |
| 2026 Q1 | 51 | $654M | −8.9% | 13F-HR | 5/15/2026 | 000130692326000004 |
| 2025 Q4 | 49 | $718M | +33.0% | 13F-HR | 2/17/2026 | 000130692326000002 |
| 2025 Q3 | 44 | $540M | +14.9% | 13F-HR | 11/14/2025 | 000130692325000019 |
| 2025 Q2 | 45 | $470M | −10.5% | 13F-HR | 8/14/2025 | 000130692325000016 |
| 2025 Q1 | 44 | $525M | −18.6% | 13F-HR | 5/15/2025 | 000130692325000014 |
| 2024 Q4 | 43 | $645M | −16.2% | 13F-HR | 2/14/2025 | 000130692325000010 |
| 2024 Q3 | 45 | $770M | −10.8% | 13F-HR | 11/14/2024 | 000130692324000012 |
| 2024 Q2 | 39 | $863M | −2.7% | 13F-HR | 8/14/2024 | 000130692324000010 |
| 2024 Q1 | 38 | $887M | −19.9% | 13F-HR | 5/15/2024 | 000130692324000008 |
| 2023 Q4 | 34 | $1.1B | — | RESTATEMENT | 2/15/2024 | 000130692324000007 |
| 2023 Q4 | 34 | $1.1B | +4.7% | 13F-HR | 2/14/2024 | 000130692324000002 |
| 2023 Q3 | 29 | $1.1B | −14.6% | 13F-HR | 11/14/2023 | 000130692323000014 |
| 2023 Q2 | 30 | $1.2B | +2.6% | 13F-HR | 8/14/2023 | 000130692323000012 |
| 2023 Q1 | 30 | $1.2B | +2.9% | 13F-HR | 5/15/2023 | 000130692323000011 |
| 2022 Q4 | 29 | $1.2B | −7.3% | 13F-HR | 2/14/2023 | 000130692323000009 |
| 2022 Q3 | 32 | $1.3B | +10.3% | 13F-HR | 11/14/2022 | 000130692322000016 |
| 2022 Q2 | 33 | $1.1B | −11.3% | 13F-HR | 8/15/2022 | 000130692322000015 |
| 2022 Q1 | 35 | $1.3B | −17.4% | 13F-HR | 5/16/2022 | 000130692322000014 |
| 2021 Q4 | 37 | $1.6B | −5.6% | 13F-HR | 2/14/2022 | 000130692322000004 |
| 2021 Q3 | 42 | $1.7B | — | 13F-HR | 11/15/2021 | 000130692321000026 |
About
Palo Alto Investors LP
23 processed 13Fs on this site · 2021 Q3–2026 Q2